AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, 6-aminopenicillanic acid derivatives	4347	1538-09-6

Description:

Molecule	Description
Synonyms: benzathine benzylpenicillin penicillin G benzathine benzylpenicillin benzathine benzylpenicillin benzathine hydrate stelues	Semisynthetic antibiotic prepared by combining the sodium salt of penicillin G with N,N'-dibenzylethylenediamine. Molecular weight: 909.13 Formula: C48H56N6O8S2 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 89.54 ALOGS: ROTB: None

Molecule

Description

Synonyms:

benzathine benzylpenicillin
penicillin G benzathine
benzylpenicillin benzathine
benzylpenicillin benzathine hydrate
stelues

Semisynthetic antibiotic prepared by combining the sodium salt of penicillin G with N,N'-dibenzylethylenediamine.

Molecular weight: 909.13
Formula: C48H56N6O8S2
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 89.54
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
3.60	g	P

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	25 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
June 27, 1952	FDA	KING PHARMS
Dec. 1, 2010	PMDA	MDKKK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Recalled product administered	374.26	46.30	47	646	768	90626986
Drug hypersensitivity	133.45	46.30	66	627	463543	90164211
Neonatal gastrointestinal disorder	76.37	46.30	9	684	81	90627673
Congenital syphilis	73.01	46.30	7	686	3	90627751
Neonatal respiratory depression	69.36	46.30	9	684	187	90627567
Embolia cutis medicamentosa	66.25	46.30	10	683	633	90627121
Premature baby	46.40	46.30	14	679	25063	90602691

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Recalled product administered	528.85	41.63	71	859	654	42619751
Embolia cutis medicamentosa	320.22	41.63	42	888	312	42620093
Jarisch-Herxheimer reaction	73.03	41.63	13	917	790	42619615

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Recalled product administered	889.81	32.10	114	1418	1168	110586599
Embolia cutis medicamentosa	354.04	32.10	49	1483	914	110586853
Drug hypersensitivity	94.23	32.10	65	1467	454025	110133742
Jarisch-Herxheimer reaction	86.95	32.10	15	1517	1202	110586565
Neonatal gastrointestinal disorder	39.43	32.10	5	1527	45	110587722
Foetal heart rate disorder	39.05	32.10	5	1527	49	110587718
Neonatal respiratory depression	36.38	32.10	5	1527	87	110587680

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01CE08	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase sensitive penicillins
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:36047	antibacterial drug
CHEBI has role	CHEBI:53000	epitope
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:88188	drug allergen
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:50748	antipsoriatic
CHEBI has role	CHEBI:64946	anti-HIV agent

Related Drugs by ATC class:

J01CE Beta-lactamase sensitive penicillins 9 drugs

azidocillin benzathine phenoxymethylpenicillin benzylpenicillin clometocillin penamecillin pheneticillin phenoxymethylpenicillin procaine benzylpenicillin propicillin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Scarlet fever	indication	30242009	DOID:8596
Pneumonia due to Streptococcus	indication	34020007
Erysipelas	indication	44653001	DOID:11330
Syphilis excluding neurosyphilis	indication	76272004
Streptococcal infectious disease	indication	85769006
Pneumococcal pneumonia	indication	233607000
Streptococcus pyogenes infection	indication	302809008
Kidney disease	contraindication	90708001	DOID:557
Infectious mononucleosis	contraindication	271558008	DOID:8568
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

Species	Use	Relation
Cattle	Bacterial infections	Indication
Cattle	Bacterial pneumonia caused by Streptococcus spp	Indication
Cattle	Bacterial pneumonia caused by Actinomyces pyogenes	Indication
Cattle	Bacterial pneumonia caused by Staphylococcus aureus	Indication
Cattle	Upper respiratory infections caused by A pyogenes	Indication
Cattle	Blackleg (Clostridium chauvoei)	Indication
Cattle	Prophylaxis of bovine shipping fever	Indication
Dogs	Bacterial infections	Indication
Horses	Bacterial infections	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Longicil Fortified	Zoetis Inc.	2
Dura-biotic, Flo-cillin	Zoetis Inc.	2
Dual-Cillin, Pen BP-48	Huvepharma EOOD	2
Combi-PEN-48	Bimeda Animal Health Limited	2

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL
Beta-lactamase TEM	Enzyme		BLAT_ECOLX		Ki	4.70		CHEMBL

External reference:

ID	Source
4017439	VUID
N0000145827	NUI
41372-02-5	SECONDARY_CAS_RN
4017439	VANDF
4017440	VANDF
C0030829	UMLSCUI
CHEBI:51352	CHEBI
CHEMBL3989515	ChEMBL_ID
25137901	PUBCHEM_CID
7980	RXNORM
5244	MMSL
d07727	MMSL
002683	NDDF
004977	NDDF
323389000	SNOMEDCT_US
323404007	SNOMEDCT_US
75247008	SNOMEDCT_US
78507004	SNOMEDCT_US
D010401	MESH_DESCRIPTOR_UI
C0030827	UMLSCUI
DB01053	DRUGBANK_ID
5904	PUBCHEM_CID
RIT82F58GK	UNII
CHEBI:18208	CHEBI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1016	INJECTION, SUSPENSION	1200000 [iU]	INTRAMUSCULAR	NDA	25 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1666	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	25 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	50090-1815	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	24 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5932	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	22 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	60793-600	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	60793-601	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN C-R 900/300	HUMAN PRESCRIPTION DRUG LABEL	2	60793-602	INJECTION, SUSPENSION	900000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-700	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-701	INJECTION, SUSPENSION	1200000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-702	INJECTION, SUSPENSION	2400000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	68258-8910	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	24 sections
Lentocilin	HUMAN PRESCRIPTION DRUG LABEL	1	84383-110	INJECTION, POWDER, FOR SUSPENSION	1200000 U	INTRAMUSCULAR	Unapproved drug for use in drug shortage	9 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

benzathine benzylpenicillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: